Summary:
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a range of doses compared with placebo
Qualified Participants Must:
• Be 40 to 80 years of age
•
Male and female
Qualified Participants May Receive:
May receive compenstion for time and travel